Diamonds and Dogs


Jazz Pharmaceuticals (JAZZ) wide awake. The drug stock is up 3% after the FDA extended the review period of its new drug treatment to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea. Jazz already has one marketed therapy called Xyrem for treating cataplexy and excessive daytime sleepiness in patients suffering from narcolepsy. Significantly, successful development and commercialization of JZP-110 should strengthen Jazz's sleep disorder portfolio and help boost its top line.

Defense stocks under pressure as military leaders are stepping down in the Trump administration. Lockheed Martin (LMT) is down 3%. Northrop Grumman (NOC) is down 3% even though they won a $3.6 billion Air Force contract.  The retired general's resignation came on the heels of Trump's surprise announcement that the U.S. would be pulling troops from Syria, and followed his decision to remove troops from Afghanistan. General Mattis was seen as the lone remaining grownup in Trump's Cabinet. His departure will make our European allies nervous.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.